A Study of NIDO-361 in Patients With SBMA — PIONEER KD

Spinal and Bulbar Muscular Atrophy Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06411912
Study type	Interventional
Source	Nido Biosciences, Inc.
Contact	Nido Biosciences
Phone	617-693-6819
Email	ClinicalTrials@nidobio.com
Status	Recruiting
Phase	Phase 2
Start date	March 1, 2024
Completion date	August 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04944940` - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting	`NCT03555578` - Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Completed	`NCT00303446` - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	Phase 2
Completed	`NCT02156141` - High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy	N/A
Completed	`NCT02024932` - Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy	Phase 2
Active, not recruiting	`NCT05517603` - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients	Phase 1/Phase 2
Recruiting	`NCT06169046` - A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy	Phase 2